Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Takeover rumours: BioNTech, Cardiol Therapeutics and Novo Nordisk in focus

The biotech sector has significantly lagged behind the performance of artificial intelligence and high-tech this year. This is because of high inflation, which in turn has made an imminent interest rate cut unlikely. Nevertheless, Germany’s economic condit...
André Will-Laudien | 9 days ago |

BASF and Cardiol Therapeutics recommended buys; TUI rides momentum

BASF (OTCQX:BASFY) shares have gained over 30% within six months. But is the rally in BASF shares slowly running out of steam? The fact that the stock did not rise sharply yesterday despite a significant price target increase suggests this is the case. Many experts see ...
Fabian Lorenz | April 10, 2024 |

Can NervGen keep a lid on explosive news?

Speculation of early “evidence” of successful proof-of-concept human trials sparks stock rallies Trial volunteers taking a placebo are offered the real deal in a follow-up trial as a “reward” The company&Clo...
Knox Henderson | March 20, 2024 |

Buzz on the Bullboards: Where volatility meets opportunity

It has been a wild ride for markets on Bay Street and Wall Street this week. Some indices hit lows not seen in nearly a year after a concerning inflation report, only to bounce back the next day. It is reporting season for many companies, and Stockhouse users seem...
Jonathon Brown | February 15, 2024 |

Is this stunning 'evidence' that NervGen has the goods?

This could be the signal that tiny NervGen Pharma Corp. (TSX-V:NGEN; OTCQX:NGENF) is destined to be one of the top performing biotech startup stocks this year. It came in a seemingly innocuous podcast interview about the company’s ongoing Phase 1b/2...
Knox Henderson | February 1, 2024 |

Theralase is raising up to $5.3M to complete bladder cancer study

Theralase Technologies is announcing a brokered financing raise for up to C$5.3 million Proceeds of the financing will be used to further the Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study Ruvidar is designed to destroy solid core tum...
Coreena Robertson | November 6, 2023 |

Buzz on the Bullboards: Interest rates are still high

Stocks on both sides of the border have wilted in this short trading week. Stocks have since suffered after the Bank of Canada said this week that it would hold its key interest rate at 5 per cent , a 22-year high. The rate pause is in line with economist expectation...
Jonathon Brown | September 7, 2023 |

Progress for radiology drugs and medical imaging company

Voyageur Pharmaceuticals ( TSXV:VM ) ( OTC:VYYRF ) is focused on vertically integrating the barium, iodine and carbon contrast imaging market – think radiology drugs and medical imaging. Its business plan is set to generate immediate cash flow by partnering with thir...
Shoran Devi | June 12, 2023 |

NetraMark Holdings, bridging an important pharmaceutical industry gap

NetraMark Holdings is a tech company, looking to identify and fill current gaps in the pharmaceutical industry. The Toronto-based company offers its proprietary algorithms to change the way in which Artificial Intelligence is used in the field, uncovering insights fro...
Simon Druker | April 27, 2023 |

Buzz on the Bullboards: Bulls on the Buzzboards

Do you believe in parallel dimensions, alternate realities? Somewhere where there is no COVID, European tensions are just that – tense, market volatility is kept to a minimum. It is here, perhaps, in the inversed Buzz, where everything is “fine”...
Stockhouse Editorial | March 9, 2022 |
1 2 3 4 5 6 7 8 9 10 ...